MAM
REGN icon

Marquette Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Marquette Asset Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$11.4K Buy
15
+1
+7% +$756 ﹤0.01% 248
2026
Q2 		$8.73K Hold
14
– – ﹤0.01% 330
2026
Q1 		$10.8K Hold
14
– – ﹤0.01% 241
2025
Q4 		$10.8K Hold
14
– – ﹤0.01% 223
2025
Q3 		$7.87K Buy
+14
New +$7.92K ﹤0.01% 254

Other funds holding REGN

GA
GuoLine Advisory Singapore $1.16B AUM 31.35% 1-Year Est. Return
AP
Atwood & Palmer Kansas City, Missouri $1.95B AUM 16% 1-Year Est. Return
MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
SBWIC
Schaper Benz & Wise Investment Counsel Neenah, Wisconsin $1.51B AUM 27.44% 1-Year Est. Return
NPPM
North Point Portfolio Managers Orange Village, Ohio $595M AUM 14.89% 1-Year Est. Return
JC
Jacobs & Co San Francisco, California $1.16B AUM 34.03% 1-Year Est. Return
MPWT
MassMutual Private Wealth & Trust Windsor, Connecticut $3.79B AUM 19.33% 1-Year Est. Return
IWS
Insight Wealth Strategies San Ramon, California $1.01B AUM 28.81% 1-Year Est. Return
VC
Veracity Capital Atlanta, Georgia $372M AUM 32.95% 1-Year Est. Return
CPBTD
Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return

Marquette Asset Management's REGN Position: Q3 2026 in Review

Marquette Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 7.1% in Q3 2026, buying an estimated $756 and bringing the position to 15 shares worth $11.4K. The position accounts for ﹤0.01% of the portfolio, ranked #248.

Marquette Asset Management first reported a position in REGN in Q3 2025 and has held it in 5 quarters since. 54 funds tracked by Wall St. Rank hold REGN as of Q3 2026.

  • Marquette Asset Management held 15 shares of Regeneron Pharmaceuticals worth $11.4K as of Q3 2026.
  • Marquette Asset Management bought 1 Regeneron Pharmaceuticals share in Q3 2026, an estimated $756.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Marquette Asset Management's portfolio in Q3 2026, its #248 holding.
  • Marquette Asset Management first reported a position in Regeneron Pharmaceuticals in Q3 2025 and has held it in 5 quarters since.
  • 54 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2026.

Based on Marquette Asset Management's 13F filing for Q3 2026, filed 9 Oct 2026.